We’d Rather
Buy the Future
Than Wait For It

Peptides are short chains of amino acids that act as biological signals in the body and can be injected with a therapeutic intent. Among them, the very popular GLP-1 weight-loss drugs, but also compounds for skincare, injury recovery, performance optimization, or longevity. Some are already FDA-approved. Most aren’t. They’re available for purchase as “research chemicals,” “not for human use,” from unregulated online vendors: these are “gray market peptides.” And the question that has dominated coverage for a year is whether people should be using them at all.

But America has already answered.

Finnrick was founded to help the US public navigate the safety of gray market peptides. We test samples for identity, purity, and quantity, then publish the results to hold vendors and labs to account. Since opening our free testing service a year ago, over 7,000 people have filed nearly 18,500 test requests, each one naming a product they purchased and asking us to verify what’s in it. Finnrick now holds a unique dataset tracking what peptides Americans are actually buying on the gray market. No regulator, lab, or vendor measures consumer demand at this scale.

This Isn’t (Just) About Cheaper Drugs

The cost and risk story is real, and it’s been well told: priced-out patients buying gray-market versions of approved pharmaceuticals. It’s a third of the story: 34% of test requests are for FDA-approved molecules where cost is the likely motive. The other 66% are for compounds that don’t exist in the licensed market. Not at a pharmacy. Not with a prescription. Not at any price.

These are people making a deliberate choice to access something the regulatory system hasn’t gotten to yet. The cost story is one chapter. Two thirds of the market would rather buy the future than wait for it.

The People Are Buying

Mapping every product to its FDA status and primary therapeutic intent reveals two things at once: what people want, and what the regulated system doesn’t provide.

The matrix makes the structural gap visible: three of five therapeutic categories have zero FDA-approved options. Every vial purchased in those columns comes from the gray market, not because it’s cheaper, but because it doesn’t exist in the regulated system at all. GLP-1 agonists (Retatrutide, Tirzepatide, Semaglutide, Cagrilintide) account for 63% of all requests: weight management dominates. But the remaining 37% spans injury recovery, cosmetics, performance, and longevity: demand the pharmaceutical system simply doesn’t serve. And this data is solid: quarterly volume has nearly quadrupled in under a year, from 1,900 requests in Q2 2025 to over 7,100 in Q1 2026.

This is shifting. In the past couple of weeks, following an announcement by HHS Secretary Robert F. Kennedy Jr., the FDA removed twelve peptides from its Category 2 “do not compound” list, including BPC-157, GHK-Cu, MOTS-c, and Melanotan II. A Pharmacy Compounding Advisory Committee review is scheduled for this summer. It is a meaningful signal, but not a resolution: these compounds remain unapproved drugs, and the review’s outcomes are not yet known.

Five Products, Different Motivations

Retatrutide: Buying the Future

A triple-agonist weight loss compound in Phase 3 trials, developed by Eli Lilly. Not approved anywhere in the world. No pharmacy dispenses it. No prescription exists. Every vial on the market was supplied by a research chemical company or a peptide synthesis lab.

The people sending us Retatrutide samples for testing are making a choice. They read the trial data and decided they’re not willing to wait three years for approval. They use Finnrick to confirm what they bought is what the vendor said it was.

Tirzepatide: The Cost Story

Already FDA-approved as Mounjaro and Zepbound. Available at any pharmacy, with a prescription, for over $1,000 a month without insurance, or through the compounding maze. Gray-market tirzepatide is a streamlined purchase at a fraction of the cost. These buyers know the molecule works. Their question is narrower: is this specific vial actually Tirzepatide, at the concentration the label claims?

GHK-Cu: Beauty and Longevity but no Pharma

A naturally occurring copper peptide, first isolated in 1973, used in skincare, wound healing, and anti-aging. No pharmaceutical company developing it. No clinical trials seeking FDA approval. No regulatory pathway underway. The #3 most-requested product on Finnrick, driven not by clinical trial data but by skincare forums, TikTok, and the beauty and wellness community.

Tesamorelin: Off-Label Optimization

FDA-approved as Egrifta for a single narrow indication: HIV-associated lipodystrophy. In practice, people are seeking it through off-label prescription or the gray market for body composition, fat reduction, and anti-aging, uses it has not been approved for.

BPC-157: Animal Data, Human Demand

A synthetic peptide derived from a protein found in gastric juice, studied in animal models for wound healing, tendon repair, and gut health. Never tested in a human clinical trial, let alone approved. And yet, this is one of the most established compounds in the gray-market peptide community, used by athletes, fitness enthusiasts, and biohackers for injury recovery.

The Bigger Picture

The five products are the edge of a dataset spanning more than forty compounds and over eighteen thousand decisions. What connects someone buying Retatrutide, GHK-Cu, or BPC-157 isn’t price sensitivity, but a decision: I am willing to make my own call on this. And then the action that follows: I will access it anyway. Agency and access are the same act.

This gets framed as risk-taking. What we see is over 18,000 test requests, purchases that happened already, from people navigating the gray market, deliberately, and asking for better information as they go.

And the behavior is compounding: volume has nearly quadrupled in under a year. We aren’t waiting for regulatory clarity or media approval: gray-market peptides are inventing a new normal and, increasingly, demanding trust signals to match that pace.

That’s where Finnrick sits. Not an advocate, and certainly not a gatekeeper, but trust infrastructure: independent measurement, public data, and pressure on vendors and labs to act right. A market that chooses for itself also has to verify for itself.

People would rather buy the future than wait for it.